Deucravacitinib, a type of TYK2 inhibitor, can potentially exhibit superior efficacy and safety compared to other JAK inhibitors in psoriasis treatment, possibly owing to its more specific and targeted mechanism of action in immune response. The gene discussed is TYK2; the disease is psoriasis.